ZNF546 Inhibitors
Chemical inhibitors of ZNF546 can achieve functional inhibition through various points of intervention in the signaling pathways that modulate the activity of this protein. PD 98059 and U0126 are two such inhibitors that specifically target the MAP kinase kinase (MEK), an enzyme responsible for the activation of extracellular signal-regulated kinase (ERK). By preventing MEK from phosphorylating ERK, these inhibitors indirectly prevent the activation of ZNF546, assuming that ZNF546's function is regulated via the MAPK/ERK pathway. Similarly, GW5074 operates one step further upstream as a Raf-1 kinase inhibitor, which is also part of the MAPK/ERK pathway. By inhibiting Raf-1 kinase, GW5074 disrupts the activation of MEK and consequently ERK, leading to the inhibition of ZNF546 if its activity is contingent upon this signaling cascade.
On a different axis, SP600125 and SB203580 target the c-Jun N-terminal kinase (JNK) and p38 MAP kinase, respectively. The inhibition of these kinases by SP600125 and SB203580 can block the phosphorylation of substrates that may regulate ZNF546, thereby inhibiting its function. Additionally, PI3K inhibitors such as LY294002 and Wortmannin suppress the PI3K/AKT pathway, which leads to reduced activity of AKT, a kinase that could be necessary for ZNF546 activation. Triciribine specifically inhibits AKT, further preventing the activation of ZNF546 if its function is AKT-dependent. PP2, which inhibits Src family tyrosine kinases, can also result in the functional inhibition of ZNF546 by blocking phosphorylation events that might be crucial for its activation. Lastly, PD168393 and Dasatinib operate by inhibiting EGFR tyrosine kinase and several tyrosine kinases, respectively.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MAP kinase kinase (MEK), which is upstream of ERK. It inhibits MEK activation and thus prevents the phosphorylation of ERK. As ZNF546 is a zinc finger protein that may be regulated by the MAPK/ERK pathway, inhibition of this pathway by PD 98059 could lead to the functional inhibition of ZNF546 by preventing its phosphorylation-dependent activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 acts similarly to PD 98059 as a selective inhibitor of MEK. By preventing the activation of MEK, U0126 blocks the phosphorylation of ERK, potentially leading to the functional inhibition of ZNF546 by hindering its activation process that could depend on the MAPK/ERK signaling pathway. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is an inhibitor of Raf-1 kinase, a component upstream of MEK in the MAPK/ERK pathway. By inhibiting Raf-1 kinase, GW5074 would block the activation of MEK and subsequently ERK, which could lead to functional inhibition of ZNF546 by impeding its phosphorylation and activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which might phosphorylate substrates that regulate transcription factors such as ZNF546. By inhibiting JNK, SP600125 could lead to functional inhibition of ZNF546 by preventing its potential phosphorylation and activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. Since p38 MAP kinase is involved in phosphorylating various substrates that affect transcription factors, SB203580 could inhibit ZNF546 by blocking phosphorylation events that would otherwise contribute to ZNF546's functional activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K), which is upstream of AKT. Inhibiting PI3K with LY294002 could lead to decreased AKT activation, which might be necessary for the functional activation of ZNF546, leading to its inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that could reduce the activation of AKT. By doing so, wortmannin may functionally inhibit ZNF546 by preventing signaling events required for ZNF546's activation that are mediated through the PI3K/AKT pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically targets the AKT signaling pathway. It inhibits the activation of AKT, which could lead to the functional inhibition of ZNF546 by blocking necessary phosphorylation events for ZNF546's activation process. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. These kinases may phosphorylate substrates that regulate ZNF546. The inhibition of Src family kinases by PP2 could lead to functional inhibition of ZNF546 by preventing phosphorylation events required for its activation. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
PD168393 inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR can activate several downstream pathways, including the MAPK/ERK pathway, which may regulate ZNF546. Inhibition of EGFR by PD168393 could lead to the functional inhibition of ZNF546 by preventing downstream signaling events necessary for its activation. | ||||||